BC Week In Review | Oct 6, 2014
Company News

Lumara Health, AMAG Pharmaceuticals deal

AMAG will acquire Lumara's maternal health business in a cash and stock deal. Lumara (formerly KV Pharmaceutical Co. ) will receive $600 million in cash and 3.2 million AMAG shares worth about $74.4 million based on...
BC Week In Review | Oct 6, 2014
Company News

Lumara Health, Perrigo deal

Perrigo will acquire Lumara's OTC women's healthcare business for $82 million in cash. Perrigo will gain Lumara's Clindesse clindamycin phosphate and Gynazole-1 butoconazole nitrate vaginal creams and Evamist estradiol transdermal spray. Perrigo said it plans...
BC Extra | Sep 30, 2014
Company News

AMAG gains on M&A deal to add Makena

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) jumped $6.54 (28%) to $29.72 Monday on news it agreed to acquire the maternal health business of Lumara Health Inc. (Chesterfield, Mo.) -- once known as KV Pharmaceutical Co. -- for...
BC Week In Review | Dec 17, 2012
Company News

Hologic, KV Pharmaceutical genitourinary news

KV will pay Hologic $60 million by year end to settle all claims related to preterm birth drug Makena hydroxyprogesterone caproate. KV, which has rights to the long-acting 17p from Hologic, filed for Chapter 11...
BC Week In Review | Dec 5, 2011
Clinical News

EvaMist regulatory update

FDA updated the label of EvaMist estradiol metered-dose transdermal spray to include a boxed warning that breast budding, breast masses and gynecomastia have been reported in children following unintentional secondary exposure to the drug. Acrux...
BC Week In Review | Aug 9, 2010
Clinical News

EvaMist estradiol MDTS regulatory update

FDA issued a warning about inadvertent exposure of EvaMist to children and animals through skin contact that could result in adverse effects. Since the drug was approved in July 2007 through June 2010, FDA said...
BC Week In Review | Apr 5, 2010
Company News

KV endocrine news

KV reduced headcount by 289 (42%) to 391 to save cash. KV markets EvaMist estradiol transdermal spray in the U.S. to treat moderate to severe vasomotor symptoms due to menopause. KV has rights to the...
BC Week In Review | Oct 5, 2009
Company News

Acrux, HRA Pharma sales and marketing update

HRA received exclusive rights to market and distribute Acrux's transdermal estradiol spray to treat symptoms of menopause in France, Germany, the U.K., Italy, Spain, Greece, Turkey and Cyprus. HRA will be responsible for obtaining marketing...
BC Week In Review | Aug 18, 2008
Company News

Acrux, KV Pharmaceutical deal

The companies expanded KV’s rights to use Acrux’s spray technology to include up to six new compounds. KV already markets Acrux’s EvaMist estradiol transdermal spray in the U.S. to treat moderate to severe vasomotor symptoms...
BC Extra | Aug 6, 2008
Top Story

Vivus raises $65 million

Vivus (NASDAQ:VVUS) raised $65 million through the sale of 8.4 million shares at $7.77 in a registered direct offering to undisclosed institutional investors. The share price is a 7% discount to Vivus' close of $8.34...
Items per page:
1 - 10 of 45